BRIEF—Celyad announces pricing of $47.3 million global offering

Belgium’s Celyad today announced the pricing of a global offering of 1,800,000 ordinary shares.

This comprised of 523,913 ordinary shares in the form of American Depositary Shares (ADSs) offered in the USA, Canada and certain countries outside of Europe at a price per ADS of $26.28, and 1,276,087 ordinary shares in Europe and certain countries outside of the USA and Canada in a concurrent private placement at a price per share of 22.29 euros (the “global offering”).

Each ADS represents the right to receive one ordinary share.

The price per ADS was determined based on an exchange rate of $1.1789 per euro.

The gross proceeds to Celyad from the global offering are expected to be approximately $47.3million (around 40.1 million euros), before deducting underwriting commissions and estimated offering expenses.

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies.